<DOC>
	<DOCNO>NCT00200655</DOCNO>
	<brief_summary>Therapeutic strategy multiple sclerosis ( MS ) essentially base use immunomodulatory agent interferon b glatirmere acetate , efficacy quite limited , well tolerate high cost . Recent work show immunomodulatory effect HMG-CoA reductase inhibitor ( so-called `` statin '' ) . In experimental allergic encephalopathy , murine model MS , statins inhibit onset progression disease shift Th1 towards Th2 cytokine production . Other vitro study suggest ability statin inhibit lymphocyte migration blood brain barrier . Furthermore , open label human study MS , statin regimen associate decreased lesional activity assess MRI . Statins well tolerate drug , use many year , low cost putative efficacy MS . The investigator suggest test pravastatin safety efficacy MRI criterion double-blind , placebo-controlled study 40 patient relapsing-remitting MS .</brief_summary>
	<brief_title>Safety Efficacy Pravastatin Relapsing-remitting Multiple Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Pravastatin</mesh_term>
	<criteria>Relapsing remit MS diagnosis define McDonald criterion ( McDonald et al. , 2001 ) current disease modifying therapy ( interferon , copaxone immunosuppressant drug ) since least 3 month EDSS score &lt; 5 . At least one gadolinium positive lesion MRI selection phase need . No current statin therapy . Normal renal hepatic biological test . No current pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>June 2008</verification_date>
</DOC>